Shares of Theravance (THRX) remain in limbo after being halted by Nasdaq earlier this morning,...
Shares of Theravance (THRX) remain in limbo after being halted by Nasdaq earlier this morning, as the FDA meets today to discuss the company's new drug application for Breo Ellipta, a dry powder inhaler that treats chronic obstructive pulmonary disease. The drug is being sponsored by GlaxoSmithKline (GSK -0.9%).
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs